Detalhe da pesquisa
1.
Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy.
J Infect Dis
; 228(9): 1280-1291, 2023 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37395474
2.
Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study.
Ann Rheum Dis
; 2022 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641124
3.
Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study.
Antimicrob Agents Chemother
; 61(7)2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28507108
4.
Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects.
Antimicrob Agents Chemother
; 61(1)2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27799203
5.
Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects.
J Antimicrob Chemother
; 72(3): 820-828, 2017 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27999038
6.
Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis.
Retrovirology
; 12: 30, 2015 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25889234
7.
ABX464 (Obefazimod) Upregulates miR-124 to Reduce Proinflammatory Markers in Inflammatory Bowel Diseases.
Clin Transl Gastroenterol
; 14(4): e00560, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36573890
8.
Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis.
J Crohns Colitis
; 17(10): 1689-1697, 2023 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37129565
9.
Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models.
Mol Cancer Ther
; 21(12): 1788-1797, 2022 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36198025
10.
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
Lancet Gastroenterol Hepatol
; 7(11): 1024-1035, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36075249
11.
Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases.
Drug Discov Today
; 26(4): 1030-1039, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33387693
12.
Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study.
J Virus Erad
; 5(1): 10-22, 2019 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30800421
13.
Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing.
Sci Rep
; 9(1): 792, 2019 01 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30692590
14.
RNA sequencing analysis of activated macrophages treated with the anti-HIV ABX464 in intestinal inflammation.
Sci Data
; 4: 170150, 2017 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29039845
15.
The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages.
Sci Rep
; 7(1): 4860, 2017 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28687795
16.
RabGEF1 is a negative regulator of mast cell activation and skin inflammation.
Nat Immunol
; 5(8): 844-52, 2004 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15235600